By Anthony O. Goriainoff

AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment--with or without chemotherapy--showed disease control rates of 92% and 93% respectively in patients with previously untreated advanced or metastatic non-small cell lung cancer.

The Anglo-Swedish pharma giant said Monday that the results reinforced its confidence in this being a potential treatment option for patients with this type of lung cancer.

"Three ongoing pivotal trials are evaluating datopotamab deruxtecan and immune checkpoint inhibitor combinations in first-line advanced non-small cell lung cancer," AstraZeneca said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

September 11, 2023 02:40 ET (06:40 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Nov 2023 a Dic 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Dic 2022 a Dic 2023 Clicca qui per i Grafici di Astrazeneca